Theranostic Platforms Proposed for Cancerous Stem Cells: A Review

Author(s): Payam Zarrintaj, Farnaz Mostafapoor, Peiman Brouki Milan, Mohammad Reza Saeb*.

Journal Name: Current Stem Cell Research & Therapy

Volume 14 , Issue 2 , 2019

Become EABM
Become Reviewer

Abstract:

It is next-to-impossible not to accept that cancer takes a position as the main cause of the global burden of disease, for it is hard to ignore the outnumbered people dying from cancer. Looking at the statistics proves that progress in cancer therapy is always beyond cancer in a race of pessimism about the future; for various kinds of cancers yearly cause death in the world, whereas the conventional and even modern therapies often exhibit lack of reliability in the treatment of cancer. In principle, various reasons are identified for cancer resistance and recurrence. Recognizing the cells/tissue from which cancer takes origin enables its early detection, and optimistically saying, protection of patients against death. It has been recognized that cancer stem cells are responsible for cancer cell proliferation and metastasis. Conventional therapies cannot eradicate the cancer stem cell; therefore, cancer recurrence is unavoidable. In this regards, designing smart platforms with specific properties is an essential step in cancer treatment. Theranostic platforms have facilitated the cancer diagnosis and treatment, simultaneously. In this respect, several types of smart materials have been designed to detect and cure cancer. Cancer stem cell as a root of the cancerous tumor should be eradicated to achieve the complete treatment; hence, cancer stem cell mechanism must be known precisely to design an appropriate platform making possible to encounter with cancer stem cell. In this review paper, various therapeutic and diagnostic techniques of cancerous stem cell are discussed to pave a way for designing proper platforms for cancer eradication.

Keywords: Cancer stem cell, theranostic, cancer therapy, drug delivery, phenotypes, cancer death rates.

[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.
[2]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
[3]
Nejadmoghaddam M-R, Zarnani A-H, Ghahremanzadeh R, Ghods R, Mahmoudian J, Yousefi M, et al. Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy. Sci Rep 2017; 7: 13373.
[4]
Saeedi M, Vahidi O, Goodarzi V, Saeb MR, Izadi L, Mozafari M. A new prospect in magnetic nanoparticle-based cancer therapy: Taking credit from mathematical tissue-mimicking phantom brain models. Nanomedicine. NBM 2017; 13: 2405-14.
[5]
Cheng L, Swartz M, Zhao H, et al. Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev 2012: cebp. 1089.2011
[6]
Babanejad N, Farhadian A, Omrani I, Nabid MR. Design, characterization and in vitro evaluation of novel amphiphilic block sunflower oil-based polyol nanocarrier as a potential delivery system: Raloxifene-hydrochloride as a model. Mater Sci Eng C 2017; 78: 59-68.
[7]
Bai X, Ni J, Beretov J, Graham P, Li Y. Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev 2018. [Epub ahead of print].
[8]
Kim YJ, Siegler EL, Siriwon N, Wang P. Therapeutic strategies for targeting cancer stem cells. J Cancer Metastasis Treat 2016; 8: 234.
[9]
Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 2013; 13: 727.
[10]
Chen K, Huang Y-h, Chen J-l. Understanding and targeting cancer stem cells: Therapeutic implications and challenges. Acta Pharmacol Sin 2013; 34: 732.
[11]
Simões BM, O’Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro A, et al. Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity. Cell Reports 2015; 12: 1968-77.
[12]
Bleau A-M, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009; 4: 226-35.
[13]
Tonigold M, Simon J, Estupiñán D, et al. Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona. Nat Nanotech 2018. [Epub ahead of print]
[14]
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
[15]
Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396.
[16]
Gilbert CA, Ross AH. Cancer stem cells: Cell culture, markers, and targets for new therapies. J Cell Biochem 2009; 108: 1031-8.
[17]
Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504.
[18]
Dalerba P, Dylla SJ, Park I-K, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-63.
[19]
O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nat 2007; 445: 106.
[20]
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
[21]
Zinzi L, Contino M, Cantore M, Capparelli E, Leopoldo M, Colabufo NA. ABC transporters in CSCs membranes as a novel target for treating tumor relapse. Front Pharmacol 2014; 5: 163.
[22]
Klonisch T, Wiechec E, Hombach-Klonisch S, et al. Cancer stem cell markers in common cancers–therapeutic implications. Trends Mol Med 2008; 14: 450-60.
[23]
Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
[24]
Simeone DM. Pancreatic cancer stem cells: Implications for the treatment of pancreatic cancer. Clin Cancer Res 2008; 14: 5646-8.
[25]
Smalley M, Piggott L, Clarkson R. Breast cancer stem cells: Obstacles to therapy. Cancer Lett 2013; 338: 57-62.
[26]
Mirabbasi F, Dorkoosh FA, Moghimi A, Shahsavari S, Babanejad N, Seifirad S. Preparation of mesalamine nanoparticles using a novel polyurethane-chitosan graft copolymer. Pharm Nanotechnol 2017; 5: 230-9.
[27]
Fan F, Wang R, Boulbes DR, et al. Macrophage conditioned medium promotes colorectal cancer stem cell phenotype via the hedgehog signaling pathway. PLoS One 2018; 13: e0190070.
[28]
Pyczek J, Buslei R, Schult D, et al. Hedgehog signaling activation induces stem cell proliferation and hormone release in the adult pituitary gland. Sci Rep 2016; 6: 24928.
[29]
Gupta S, Takebe N, LoRusso P. Targeting the Hedgehog pathway in cancer. Ther Adv Med Oncol 2010; 2: 237-50.
[30]
Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: A new paradigm in immunotherapy? MAbs. Taylor & Francis 2009; pp. 12-25.
[31]
Morrison R, Schleicher SM, Sun Y, et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011; 2011: 941876.
[32]
Ding P-R, Tiwari AK, Ohnuma S, et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One 2011; 6: e19329.
[33]
Šubr V, Koziolová E, Sivák L, Říhová B, Kovář M, Ulbrich K. Polymer inhibitors of Abc transporter overcoming multidrug resistance: Synthesis, characterization and in vitro evaluation. J Control Release 2015; 213: e107-8.
[34]
Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancers inflammatory rootsClin Cancer Res 2011: Clincanres 2743011
[35]
Charles NA, Holland EC. The perivascular niche microenvironment in brain tumor progression. Cell Cycle 2010; 9: 3084-93.
[36]
Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG, Wang B. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem 2013; 5: 553-72.
[37]
Tao W, Ji X, Zhu X, et al. Two‐Dimensional Antimonene‐Based Photonic Nanomedicine for Cancer Theranostics. Adv Mater 2018; 1802061.
[38]
Zarrintaj P, Urbanska AM, Gholizadeh SS, Goodarzi V, Saeb MR, Mozafari M. A facile route to the synthesis of anilinic electroactive colloidal hydrogels for neural tissue engineering applications. J Colloid Sci 2018; 516: 57-66.
[39]
Baghaei B, Saeb MR, Jafari SH, et al. Modeling and closed‐loop control of particle size and initial burst of PLGA biodegradable nanoparticles for targeted drug delivery. J Appl Polym Sci 2017; 134: 45145.
[40]
Mohebbi S, Nezhad M, Zarrintaj P, et al. Chitosan in Biomedical Engineering: A Critical Review. Curr Stem Cell Res Ther 2018. [Epub ahead of print].
[41]
Yaari Z, Da Silva D, Zinger A, et al. Theranostic barcoded nanoparticles for personalized cancer medicine. Nat Commun 2016; 7: 13325.
[42]
Omrani I, Babanejad N, Shendi HK, Nabid MR. Preparation and evaluation of a novel sunflower oil‐based waterborne polyurethane nanoparticles for sustained delivery of hydrophobic drug. Eur J Lipid Sci Technol 2017; 119: 1600283.
[43]
Omrani I, Babanejad N, Shendi HK, Nabid MR. Fully glutathione degradable waterborne polyurethane nanocarriers: Preparation, redox-sensitivity, and triggered intracellular drug release. Mater Sci Eng C 2017; 70: 607-16.
[44]
Baghaei B, Jafari SH, Khonakdar HA, Saeb MR, Wagenknecht U, Heinrich G. A multioptimization approach to assessment of drug delivery of PLGA nanoparticles: Simultaneous control of particle size and release behavior. Int J Polym Mater Po 2015; 64: 641-52.
[45]
Zarrintaj P, Bakhshandeh B, Saeb MR, et al. Oligoaniline-based conductive biomaterials for tissue engineering. Acta Biomater 2018; 72: 16-34.
[46]
Mottaghitalab F, Kiani M, Farokhi M, et al. Targeted delivery system based on gemcitabine-loaded silk fibroin nanoparticles for lung cancer therapy. ACS Appl Mater Interfaces 2017; 9: 31600-11.
[47]
Bangaru MLY, Chen S, Woodliff J, Kansra S. Curcumin (diferuloylmethane) induces apoptosis and blocks migration of human medulloblastoma cells. Anticancer Res 2010; 30: 499-504.
[48]
Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther 2011; 11: 464-73.
[49]
Babanejad N, Nikjeh MMA, Amini M, Dorkoosh FA. A nanoparticulate raloxifene delivery system based on biodegradable carboxylated polyurethane: Design, optimization, characterization, and in vitro evaluation. J Appl Polym Sci 2014; 131.
[50]
Mamaeva V, Rosenholm JM, Bate-Eya LT, et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol Ther 2011; 19: 1538-46.
[51]
Conti L, Lanzardo S, Ruiu R, et al. L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents. Oncotarget 2016; 7: 66713.
[52]
Sun T-M, Wang Y-C, Wang F, et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 2014; 35: 836-45.
[53]
Liu Y, Chen C, Qian P, et al. Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nat Commun 2015; 6: 5988.
[54]
Yang C, Xiong F, Wang J, et al. Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. Nanomedicine (Lond) 2014; 9: 45-60.
[55]
Zuo Z-Q, Chen K-G, Yu X-Y, et al. Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-β signaling pathway inhibition. Biomaterials 2016; 82: 48-59.
[56]
Burke AR, Singh RN, Carroll DL, Torti FM, Torti SV. Targeting cancer stem cells with nanoparticle-enabled therapies. J Mol Biomark Diagn 2012.
[57]
Liu C, Zhao G, Liu J, et al. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J Control Release 2009; 140: 277-83.
[58]
Piao L, Zhang M, Datta J, et al. Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther 2012; 20: 1261-9.
[59]
Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011; 10(8): 1470-80.
[60]
Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 2011; 63: 24-46.
[61]
Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer 2008; 44: 2546-54.
[62]
Yu L, Liu J, Wu K, Klein T, Jiang Y, Wang J-P. Evaluation of hyperthermia of magnetic nanoparticles by dehydrating DNA. Sci Rep 2014; 4: 7216.
[63]
Ohtake M, Umemura M, Sato I, Akimoto T, Oda K, Nagasako A, et al. Hyperthermia and chemotherapy using Fe (Salen) nanoparticles might impact glioblastoma treatment. Sci Rep 2017; 7: 42783.
[64]
Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG, et al. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy Sci Transl Med 2010; 2: 55ra79-55ra79.
[65]
Galanzha EI, Kim JW, Zharov VP. Nanotechnology‐based molecular photoacoustic and photothermal flow cytometry platform for in‐vivo detection and killing of circulating cancer stem cells. J Biophotonics 2009; 2: 725-35.
[66]
Sadhukha T, Niu L, Wiedmann TS, Panyam J. Effective elimination of cancer stem cells by magnetic hyperthermia. Mol Pharm 2013; 10: 1432-41.
[67]
Burke AR, Singh RN, Carroll DL, Wood JC, D’Agostino RB, Ajayan PM, et al. The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 2012; 33: 2961-70.
[68]
Wang X, Wei F, Liu A, et al. Cancer stem cell labeling using poly (L-lysine)-modified iron oxide nanoparticles. Biomaterials 2012; 33: 3719-32.
[69]
Banerjee I, Pangule RC, Kane RS. Antifouling coatings: recent developments in the design of surfaces that prevent fouling by proteins, bacteria, and marine organisms. Adv Mater 2011; 23: 690-718.
[70]
Corbo C, Molinaro R, Tabatabaei M, Farokhzad OC, Mahmoudi M. Personalized protein corona on nanoparticles and its clinical implications. Biomater Sci 2017; 5: 378-87.
[71]
Ye J, Wu D, Wu P, Chen Z, Huang J. The cancer stem cell niche: Cross talk between cancer stem cells and their microenvironment. Tumour Biol 2014; 35: 3945-51.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 2
Year: 2019
Page: [137 - 145]
Pages: 9
DOI: 10.2174/1574888X13666181002152247
Price: $58

Article Metrics

PDF: 24
HTML: 3